Clinical Edge Journal Scan

Four-fold higher risk for interstitial lung abnormalities in RA patients with a history of smoking


 

Key clinical point: Rheumatoid arthritis (RA) increased the prevalence of interstitial lung abnormalities (ILA) in participants with a history of smoking, which in turn led to a significant increase in the mortality rate.

Major finding: ILA were ~4 times more prevalent in individuals with a history of smoking who did vs did not have RA (adjusted odds ratio 4.15; 95% CI 2.17-7.97). Among patients with RA and a record of smoking, mortality risk was ~3 times higher in those with ILA or indeterminate ILA findings vs those without ILA (adjusted hazard ratio 2.86; 95% CI 1.33-6.16).

Study details: This cross-sectional prospective study included participants with a current or past history of smoking from the COPDGene cohort, of whom 83 participants had RA and were compared with 8725 individuals without RA.

Disclosures: COPDGene was supported by the US National Heart, Lung, and Blood Institute and others. Several authors declared receiving consulting fees, grant support, research support, or having other ties with various sources.

Source: McDermott GC et al. Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicentre prospective cohort of smokers. Rheumatology (Oxford). 2023;62(SI3):SI286-SI295 (Oct 23). doi: 10.1093/rheumatology/kead277

Recommended Reading

Telitacicept shows efficacy, safety in methotrexate-resistant RA
MDedge Rheumatology
Abatacept reduced rates of progression to RA, phase 2b trial finds
MDedge Rheumatology
Conditional recommendations rule in new SARD-associated interstitial lung disease guidelines
MDedge Rheumatology
Low-dose methotrexate carries higher risk for older patients with CKD
MDedge Rheumatology
Real-world study confirms efficacy of all JAK inhibitors in RA
MDedge Rheumatology
Elevated risk for cancer in RA patients treated with DMARD
MDedge Rheumatology
Herpes zoster subunit vaccine can be recommended in JAKi-treated RA
MDedge Rheumatology
Real-world study demonstrates cons of tapering DMARD in well-controlled RA
MDedge Rheumatology
Two-fold higher risk for serious infections with tofacitinib vs bDMARD in older RA patients
MDedge Rheumatology
Meta-analysis assesses hepatitis B reactivation risk in anti-IL-6-treated RA
MDedge Rheumatology